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GENETIC DISORDERS – DEVELOPMENT
Pyridoxine effect in type I primary hyperoxaluria is associated
with the most common mutant allele
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Pyridoxine effect in type I primary hyperoxaluria is associated
with the most common mutant allele.
Background. Pyridoxine (VB6) response in type I primary
hyperoxaluria (PHI) is variable, with nearly equal numbers of
patients showing partial to complete reductions in oxaluria,
and resistance. Because high urine oxalate concentrations cause
stones and renal injury, reduction in urine oxalate excretion
is deemed favorable. Mechanisms of VB6 action on hep-
atic alanine:glyoxylate aminotransferase (AGT), the deficient
enzyme in PHI, and VB6 dose response have not been well-
characterized.
Methods. Sequencing or restriction site–generating poly-
merase chain reaction (PCR) was used for c.508 genotyping in
23 PHI patients. Pre- and post-VB6 24-hour urine oxalate ex-
cretion and VB6 dose were ascertained by retrospective chart
review.
Results. There were six c.508 G>A homozygotes (AA), eight
heterozygotes (GA), and nine patients lacking this change
(GG). Pre-VB6 urine oxalate excretion was 152 ± 39, 203 ±
68 and 206 ± 74 mg/1.73 m2/24 hours, respectively, and did not
differ [AA vs. GA (P = 0.07); AA vs. GG (P = 0.07); GA vs.
GG, (P = 0.47)]. Post-VB6 urine oxalate excretion was normal
in AA (pre- vs. post-VB6) (P < 0.001), partially reduced in GA
(P < 0.001), and unchanged in GG (P = 0.06). Urine oxalate
excretion attenuation was similar for VB6 doses (mg/kg/day)
of 1 to 4.9, 5 to 9.9, and 10 to 14.9 in AA (P = 0.41, P = 0.28,
and P = 0.11, respectively) and GA (P = 0.42, P = 0.39, and
P = 0.30, respectively) during follow-up.
Conclusion. Presence of the c.508 G>A allele confers VB6
response in PHI and VB6 doses of 5 mg/kg/day appear suffi-
cient. c.508 genotyping can be used to predict VB6 response
and guide treatment in PHI. [c represents cDNA sequence
where nucleotide position +1 corresponds to the adenine (A)
of the translation start codon ATG. Equivalent positions based
on 5′ UTR nucleotide numbering are as follows: c.508 G>A
= G630A (Gly170Arg), c.32 C>T = C154T (Pro11Leu), and
c.454 T>A = T576A (Phe152Ile)], yields highest residual AGT
activity. To test whether VB6 response might be attributable to
this allele, we performed c.508 genotyping.
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Primary hyperoxaluria type I (PHI) (McKusick
259900) is an inborn error of glyoxylate metabolism inher-
ited as an autosomal-recessive trait. Deficiency of perox-
isomal liver-specific alanine:glyoxylate aminotransferase
(AGT) (EC 2.6.1.44) causes a marked increase in hep-
atic oxalate production [1]. Excess oxalate produced can-
not be degraded and is eliminated by renal excretion,
ensuing in hyperoxaluria. High urine oxalate concentra-
tions result in calcium oxalate deposition within renal
parenchyma or stone formation within the urinary tract,
progressive renal injury leading to renal failure, and in
late stages, systemic calcium oxalate deposition causing
severe morbidity and death [2].
PHI clinical expression is diverse, with variable symp-
tom presentation and age at onset of renal failure. The
majority of patients present with symptoms related to
urolithiasis during childhood or adolescence. The pheno-
typic spectrum ranges from nephrocalcinosis and/or renal
failure in infancy to urolithiasis in adulthood and renal
failure in later life [3, 4]. To date, attempts to correlate
this clinical heterogeneity with specific mutations of the
gene coding for AGT (AGXT) or residual AGT catalytic
activity have been inconclusive [5–8].
One aspect of phenotypic expression that is of partic-
ular therapeutic relevance is pyridoxine (VB6) respon-
siveness. Since PHI pathophysiology appears due to very
high urine oxalate concentrations, with oxalate being a
recognized cellular and tissue toxin [9], any amelioration
of hepatic oxalate production and hence reduction in uri-
nary oxalate concentrations is beneficial. VB6 adminis-
tration in daily doses of 2 to 1000 mg to reduce oxalate
excretion in PHI has been noted in case reports since
1961 [10]. In 1998, based on a literature review, Toussaint
[11] concluded that approximately 20% of PHI patients
would be expected to completely normalize their urine
oxalate excretion in response to VB6, 30% would expe-
rience a partial response and 50% would be refractory
[11]. Further understanding of VB6 response in PHI has
been complicated by small numbers of patients, and a
wide range of treatment doses and duration in prior pub-
lished reports.
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Though attributed to its role as cofactor of AGT, the
molecular basis and precise mechanism for VB6 effect
in PHI remain unknown. There are no known clinical,
biochemical, or molecular markers allowing identifica-
tion of patients likely to respond to VB6. Testing of the
clinical VB6 response by measuring urine oxalate ex-
cretion before and after treatment is helpful in patients
with preserved renal function but unreliable in patients
with moderate to advanced renal insufficiency. Further-
more, many uncertainties remain regarding VB6 dosing
and time required for maximal response and permanence
of the observed response and VB6 safety, particularly at
higher doses due to potential peripheral sensory neuropa-
thy [12]. A molecular-based method for selection of VB6
responsive PHI patients would facilitate optimal treat-
ment and also provide helpful insights into a number of
these unresolved issues.
In addition to clinical diversity, phenotypic variability
at the enzyme level was recognized early. Danpure et al
[13] showed the presence of a unique “trafficking” ab-
normality among a subset of patients in whom the AGT
protein was mistargeted from its normal peroxisomal lo-
cation to mitochondria where AGT is metabolically inef-
fective in disposition of glyoxylate, a key metabolic sub-
strate and direct oxalate precursor. AGT mitochondrial
targeting is ascribed to synergistic effects of a cryptic mi-
tochondrial targeting sequence encoded by a common
polymorphism, c.32 C>T [14], and inhibition of AGT
protein dimerization by cosegregation of this and another
change, c.508 G>A [15], the most common mutation in
PHI.
Of nearly 50 AGXT mutations described [16], the c.32
C>T and c.508 G>A haplotype has been recognized to
yield highest expression of residual AGT protein and cat-
alytic activity [17] and hence was selected as the most
likely candidate allele potentially responsible for VB6
responsiveness. We here demonstrate an association be-
tween the c.508 G>A genotype and VB6 responsiveness
in 23 PHI patients.
METHODS
Participation in this Institutional Review Board ap-
proved study was offered to all PHI patients followed at
our institution. Patients provided written informed con-
sent. Of 37 participants, 23 from 22 unrelated families
had availability of pre- and post-VB6 24-hour urine ox-
alate excretion. Since in PHI plasma oxalate concentra-
tion and tissue oxalate accretion begin to rise steeply
when glomerular filtration rate (GFR) falls below 40
mL/min/1.73 m2 [18], suggesting a reduction in urine ox-
alate excretion, patients with renal clearance below this
range were excluded from the study. Clinical VB6 sensi-
tivity could not be evaluated in 13 patients due to renal
failure at presentation (N = 9) or unavailability of urine
oxalate excretion before VB6 initiation (N = 4). In one
infant only random urine oxalate to creatinine ratios were
available. The remaining 23 patients are the subject of this
report.
PHI was diagnosed by hepatic enzyme analysis con-
firming AGT deficiency in the patient (N = 17) or af-
fected sibling (N = 2) by marked hyperoxaluria with el-
evated urine glycolate and normal urine glycerate (N =
1) or by marked hyperoxaluria without secondary causes
and homozygosity for a known AGXT mutation (N =
3). Because most patients had uninterrupted VB6 treat-
ment since initially prescribed, pre- and post-VB6 urine
oxalate excretion, VB6 duration and dose were obtained
by retrospective review of medical records. Timing of ini-
tial 24-hour urine oxalate measurement after VB6 com-
mencement ranged from 1 to 14 months. Follow-up VB6
doses and corresponding urine oxalate excretion rates
were obtained retrospectively from chart review. The rec-
ommended daily allowance for VB6 in children and ado-
lescents is age-dependent, ranging 0.1 to 0.3 mg in infancy,
0.5 to 0.6 mg for ages 1 to 8 years, and 1.0 to 1.3 mg during
adolescence. The recommended daily allowance in adults
is 2.0 mg.
Urine was collected for 24 hours in a container acid-
ified with hydrochloric acid to prevent calcium oxalate
crystallization. The specimen pH was verified to be <2.0
prior to analysis. Urine oxalate was measured using the
oxalate oxidase assay (normal <40.5 mg (0.46 mmol)/24
hours) [19] and values corrected for surface area to permit
pediatric to adult comparisons [20]. Simultaneous mea-
surement of 24-hour urine creatinine verified complete-
ness of each collection. GFR was assessed by creatinine
or iothalamate clearance.
Data are expressed as mean ± SD. Paired or unpaired
Student t test was used for comparisons between groups,
as appropriate.
c.508 genotyping was performed using a restriction
site (Msp I) generating polymerase chain reaction (PCR)
and/or by direct sequencing of exon 4. Though this mu-
tation detection method has been published previously
[21], the authors designed and tested multiple primer
pairs and optimized conditions “de novo.” Introduction
of an alternate site for detection of this sequence change,
using Mse I, was also developed. Primer sequences will
be provided upon request. Hepatic enzyme analyses
were performed in laboratories of Dr. C.J. Danpure and
Dr. G. Rumsby, University College London, London,
United Kingdom, and by Dr. Marie-Odile Rolland, Ho-
pitaux de Lyon, France, in one patient.
RESULTS
Patients were grouped according to c.508 G>A
genotyping. There were six homozygotes (AA), eight
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Table 1. c.508 genotype, gender,% mean normal residual alanine:glyorylate aminotransferase (AGT) catalytic activity and immunoreactivity,
initial ages, VB6 dose and pre-/post urine oxalate excretion rates, years of follow-up, and number of urine oxalate determinations in 23 patients
with type I primary hyperoxaluria (PHI)
Initial data Follow-up data
% Mean normal Pre-VB6 urine Post-VB6 urine Urine oxalate
residual AGT AGT Dose oxalate oxalate measurements
Geno- catalytic immuno- Age VB6 mg/1.73 mg/1.73 Years of during
Patient type Gender activitya reactivity years mg/kg/day m2/24 hours m2/24 hours follow-up follow-up
1 AA M Not done Not done 30 4.0 132 33 5 5
2 AA M Not done Not done 12 5.6 105 54 8 7
3 AA M Not done Not done 10 6.9 157 38 9 13
4 AA M 12 Positive 32 3.4 198 58 3 3
5 AA M 17 Weakly+ 5 1.2 125 26 8 17
6 AA F 28 Positive 12 1.0 200 38 6 2
Mean ± SD 19 ± 8 16.8 ± 11.3 3.7 ± 2.3 152 ± 39 41 ± 12 6.5 ± 2.3 7.8 ± 5.9
7 GA F 12 Weakly + 30 3.5 274 169 12 11
8 GA M 11 Weakly + 17 2.0 300 135 3 4
9 GA M Sib of 10 3 3.3 118 92 12 9
10 GA M 6 Weakly+ 5 1.8 171 96 12 9
11 GA M 17 Weakly+ 11 16 140 100 3 4
12 GA F 1 25% 29 3.0 164 46 3 3
13 GA M 13 Weakly+ 6 5.0 193 142 18 8
14 GA M 14 Weakly+ 18 2.1 268 110 4 2
Mean ± SD 10 ± 5 14.9 ± 10.5 4.6 ± 4.7 203 ± 68 111 ± 37 8.4 ± 5.8 6.3 ± 3.4
15 GG F 7 Positive 6 4.5 261 282 14 30
16 GG F 5 Weakly+ 28 1.8 336 326 36 21
17 GG M 11 Negative 49 5.4 248 282 5 4
18 GG F Not done Not done 6 2.9 250 392 17 25
19 GG F 11 Weakly+ 4 14.9 121 227 6 13
20 GG M 7 Negative 11 10.5 154 217 2 5
21 GG M Nil Weakly+ 46 2.0 134 143 11 17
22 GG F Bx in sib 29 2.5 132 157 28 29
23 GG F Nil Not done 2 10.9 220 150 3 2
Mean ± SD 8 ± 2 19.1 ± 19.4 6.2 ± 4.8 206 ± 74 241 ± 85 13.6 ± 11.8 16.2 ± 10.8
aAGT catalytic activity, normal range 19.1 to 47.9 lmol/hour/mg protein except in patients 12 and 21 (normal range 2.75 to 8.38 lmol/hour/mg protein), patient 16
(normal range 17.9 to 38.5 lmol/hour/mg protein), and patient 23 (536 ± 140 lmol/second/kg protein). Percent mean normal AGT catalytic activity = residual measured
AGT activity/midpoint of normal range times 100. Bx in sib indicates availability of hepatic enzyme analysis in an affected sibling that is not listed in the table. For each
group (AA, GA, and GG), the corresponding mean ± SD is given under each column. To convert urinary oxalate values from milligrams to millimoles per 1.73 m2,
divide by 88.
heterozygotes (GA) and nine patients who did not pos-
sess this change (GG). Clinical and laboratory findings
are listed in Table 1. Renal clearance at initial visit was
90 ± 21 (AA), 87 ± 15 (GA), and 98 ± 26 (GG) mL/min/
1.73 m2.
Pre-VB6 urine oxalate was 152 ± 39 (AA), 203 ± 68
(GA), and 206 ± 74 (GG) mg/1.73 m2/24 hours (Table 1)
and did not differ significantly among the groups [AA vs.
GA (P = 0.07); AA vs. GG (P = 0.07); and GA vs. GG
(P = 0.47)]. Residual AGT catalytic activity was higher
in AA vs. GA (P = 0.05) and GG (P = 0.03) and com-
parable in GA vs. GG (P = 0.07). VB6 dose was similar
among the three groups (P = 0.34, P = 0.25, and P = 0.13,
respectively). Pre- and initial post-VB6 urine oxalate ex-
cretion according to genotype is shown in Figure 1. All
AA patients showed near to complete normalization of
urine oxalate post-VB6 (pre- vs. post-VB6 urine oxalate)
(P < 0.001), and seven of eight GA patients showed a
partial reduction in oxaluria (P < 0.001). The eighth GA
patient showed initial complete reduction followed by a
partial reduction during subsequent measurements. By
contrast, urine oxalate excretion was nearly 20% higher
after VB6 in GG though not statistically significant (P =
0.06).
VB6 doses varied during follow-up. Corresponding
urine oxalate excretion rates were available during 6.5 ±
2.3 (AA), 8.4 ± 5.8 (GA), and 13.6 ± 11.8 (GG) years of
follow-up. VB6 dose ranges (mg/kg/day) of 1 to 4.9, 5 to
9.9, and 10 to 14.9 showed similar urine oxalate reduction
in AA (P = 0.41, P = 0.28, and P = 0.11, respectively)
and GA (P = 0.42, P = 0.39, and P = 0.30, respectively)
(Fig. 2). No further decrease in urine oxalate excretion
was observed with doses >5 mg/kg/day in AA or GA pa-
tients. In patients lacking the c.508 G>A mutation (GG),
urine oxalate was lower at VB6 doses of 5 to 9.9 vs. 1 to 4.9
(P < 0.001) but remained markedly elevated. Urine ox-
alate did not decrease further with doses >10 (P = 0.20).
Complete (AA) VB6 response was defined as urine ox-
alate excretion rate that became normal or near normal
(0.5 to 0.7 mmol/1.73 m2/24 hours) while the patient was
receiving VB6. Partial (GA) VB6 response was defined
as a reduction in urine oxalate excretion of 30% or more
after administration of VB6. Of the patients receiving
the highest initial supplemental dose of VB6, and those
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Fig. 1. Pyridoxine effect by genotype in type I primary hyperoxaluria
(PHI). Urine oxalate excretion rates before () and after () VB6 ad-
ministration in patients homozygous (AA), heterozygous (GA), and
lacking the c.508 G>A allele (GG). Normal range for urine oxalate
excretion is <40.5 mg (0.46 mmol)/24 hours. Vertical bars indicate stan-
dard deviation.
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Fig. 2. Pyridoxine dose response by genotype in type I primary
hyperoxaluria (PHI). Urine oxalate excretion rates on VB6 doses
(mg/kg/day) of 1.0 to 4.9 (), 5 to 9.9 (), and 10 to 14.9 ( ) in pa-
tients homozygous (AA), heterozygous (GA), and lacking the c.508
G>A allele (GG). Numbers below each bar indicate the number of
measurements for each dose and genotype. Vertical bars indicate stan-
dard deviation.
remaining on the vitamin for longer than a decade (Table
1), only one patient [14] developed symptoms suggestive
of VB6 toxicity (paraesthesias). Symptoms resolved fol-
lowing VB6 discontinuation.
DISCUSSION
That VB6 administration is able to reduce urine ox-
alate excretion, and presumably hepatic metabolic pro-
duction in some, but not all PHI patients, has been known
for over 40 years. Predictability of the response and the
dose required for therapeutic effect, however, have been
unknown, and persistence of the response has been ques-
tioned. Here, we demonstrate an association between the
c.508 G>A genotype and clinical VB6 responsiveness,
establishing the first application of pharmacogenomics in
this disorder.
VB6 action on hepatic oxalate production, and in turn
on renal oxalate excretion, has been ascribed to its role
as essential cofactor of the hepatic transamination of gly-
oxylate to glycine catalyzed by AGT [22]. Whether pyri-
doxal 5′ phosphate, its active form, bestows a favorable
effect on human mutant AGT protein via conformational,
transcriptional, or prosthetic roles is not known. The
potential contribution of other VB6-mediated enzyme
systems capable of metabolizing glyoxylate, such as glu-
tamate:glyoxylate aminotransferase in cytosol of hepato-
cytes, or elsewhere as in renal tubular epithelial cells, is
also not well-defined.
Regardless of the precise mechanism, the ability of
VB6 to favorably impact glyoxylate metabolism is evi-
dent in the partial reductions to normalization of oxaluria
observed in 61% (14/23) of our patients. The clinical VB6
response was found to be proportional to the number of
copies of the c.508 G>A allele. Homozygosity and het-
erozygosity for this change appear to confer complete
and partial responses, respectively, an observation that
may be explained by the higher residual AGT catalytic
activity coded for by the A allele [17].
The AGT mitochondrial mistargeting mechanism es-
tablished to date is based on the observation that inher-
itance of the c.508 G>A and c.32 C>T changes on the
same allele causes synergistic inhibition of AGT dimer-
ization which favors entry of AGT monomers into mi-
tochondria [15]. This functional effect is referred to as
“synergistic” because neither change alone is able to re-
route AGT protein to mitochondria in vitro [23, 24]. Mi-
tochondrial protein import requires unfolded monomers
whereas peroxisomal matrix proteins are generally folded
in the cytosol and transported as fully folded tertiary
structures. Indeed, Leiper et al [24] specifically showed
that AGT dimerization in the cytosol precedes peroxiso-
mal import.
Interestingly, salvage pathway molecular chaperones
have not been directly observed within mammalian per-
oxisomal matrix, only along the membranes of these or-
ganelles [25]. Brocard et al [25] recently showed that heat
shock protein 70, a cytosolic molecular chaperone, can be
imported into peroxisomes along with unfolded peroxi-
somal matrix proteins, challenging the more uniformly
held belief that peroxisomal matrix proteins are typically
imported into peroxisomes fully folded.
These findings have potential implications for the
mechanism of action of VB6 and for therapeutic tar-
gets in PHI. Pharmacologic doses of the cofactor could
“rescue” mutant AGT protein from being targeted to
mitochondria in a process akin to conformational effects
seen with chemical and pharmacologic chaperones in en-
doplasmic reticulum [26]. AGT protein monomers could
enter peroxisomes unfolded and fully dimerize into a
functional 392-residue homodimer along with its cofactor
once inside. However, in an in vitro expression system
of a mutant AGT construct containing the c.508 G>A
and c.32 C>T changes in COS cells, neither pyridoxine
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nor pyridoxal phosphate corrected the AGT mistargeting
defect [23]. Conversely, glycerol and lowering the tem-
perature, both deemed to have a “nonspecific chemical”
effect on the stability of protein structure, satisfactorily
corrected AGT targeting from mitochondria to perox-
isomes. Moreover, unlike the in vivo situation whereby
the AGT protein appears to always be expressed and cat-
alytically active when coded by this mutant allele, similar
in vitro experiments in Escherichia coli have yielded pre-
dominantly aggregated, catalytically defunct AGT pro-
tein [15]. Additional in vitro studies, perhaps using other
expression systems, are needed to further characterize
the mechanism of VB6 action in PHI.
Data regarding longevity of clinical response to VB6 is
scarce. In our cohort, AA and GA patients sustained their
respective favorable responses over the entire follow-up
period. A single GA patient (Patient 12) initially showed
a complete response but then maintained partial VB6
responsiveness during 3 years of follow-up. Factors in-
fluencing this unusual pattern of VB6 response are not
known and require further investigation. Notably, how-
ever, though a loss or gain of VB6 response over time
has been reported in some patients [abstract; Leumann
E et al, Proceedings from the Oxalosis and Calcium Ox-
alate Stone Disease, presented by the National Institute of
Diabetes and Digestive Kidney Diseases, in cooperation
with the Oxalosis and Hyperoxaluria Foundation, p 33,
2000], we did not observe any marked variability, even
after many years of follow-up. Prospective dose response
studies are needed in AA and GA patients to more pre-
cisely define the minimum effective dose of VB6. Such
information would be beneficial to long-term patient
management.
Our results indicate that c.508 G>A genotyping can
be used to predict VB6 response and guide treatment
in PHI. In AA and GA, VB6 imparts lasting reduction
in oxaluria and patients with these genotypes should re-
ceive VB6 treatment. VB6 doses of 5 mg/kg/day appear
sufficient to achieve sustained normalization of oxaluria
in AA and a partial reduction in GA, and hence higher
doses do not appear necessary. Whether this effect is due
to higher residual enzyme activity or mitochondrial AGT
mistargeting per se is not certain.
Evaluation of VB6 dose response in patients with other
mutant alleles capable of yielding detectable mitochon-
drial AGT expression (c.454 T>A) or significant residual
AGT activity will be of interest. We have detected the
c.454 T>A change in a single GG patient from our cohort
and her observed clinical response to VB6 resembles that
of patients with c.508 G>A heterozygosity. Pending char-
acterization of VB6 effect in patients with other AGXT
mutations, a treatment trial is recommended in all GG pa-
tients. Due to uncertainties regarding VB6 efficacy and
safety in the higher dose range [13], further insights are
needed prior to implementing daily doses exceeding 10
mg/kg/day. The demonstration of an association between
the c.508 G>A genotype and VB6 responsiveness opens
the door to informed use of this valuable agent in the
treatment of PHI.
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